Reckitt Benckiser Group plc (OTCMKTS:RBGLY) Given Average Rating of “Buy” by Analysts

Reckitt Benckiser Group plc (OTCMKTS:RBGLY) has been given an average rating of “Buy” by the seven research firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and three have given a strong buy recommendation to the company.

A number of research analysts have commented on RBGLY shares. Hsbc Global Res raised Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 11th. Barclays lowered shares of Reckitt Benckiser Group from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 4th. Sanford C. Bernstein downgraded Reckitt Benckiser Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 4th. Finally, HSBC raised Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a report on Wednesday, December 11th.

Reckitt Benckiser Group Stock Down 0.6 %

Shares of OTCMKTS RBGLY opened at $13.33 on Thursday. Reckitt Benckiser Group has a fifty-two week low of $10.24 and a fifty-two week high of $15.03. The company’s 50 day simple moving average is $12.55 and its 200 day simple moving average is $12.22. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.